Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Leukemia, acute myeloid (AML), adult
Stage/Subtype:  untreated adult acute myeloid leukemia
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 109 for your search:
Start Over
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1227, NA_00071844, NCT01588951
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: PRO#1278: Flu-Bu-TBI, NCT01366612
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116428, 2012-003438-18, NCT01767467
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 to 60
Sponsor: NCI
Protocol IDs: NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, S1203, U10CA180888, U10CA032102, NCT01802333
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGI-110-04, NCT02348489
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, P30CA015704, FHCRC-2230.00, IR-6771, NCT00789776
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI
Protocol IDs: CASE1908, NCI-2009-01285, NCT01093573
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KB004-01, NCT01211691
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0788, NCI-2011-00251, NCT01289457
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1110007281; IUCRO-0327, NCT01534260
Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2011-0188, NCI-2012-01350, NCT01636609
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2498.00, NCI-2011-03362, P01CA018029, P30CA015704, NCT01640301
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2012-0265, NCI-2012-02072, NCT01664910
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 201303012, NCT01747499
Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2012-0434, API-01, NCI-2014-01360, NCT01756677
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: RT12-US-AML-a, NCT01795924
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 12393, NCI-2013-01141, NCT01876953
AC220 With 5-Aza or Low Dose Cytarabine
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-1047, NCI-2013-02274, P50 CA100632, NCT01892371
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2013-0099, NCI-2013-01665, NCT01893320
Oral Rigosertib in Combination With Azacitidine
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Onconova 09-08, 2013-000673-72, NCT01926587
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
Start Over